Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

5.0%

1 terminated out of 20 trials

Success Rate

93.3%

+6.8% vs benchmark

Late-Stage Pipeline

55%

11 trials in Phase 3/4

Results Transparency

64%

9 of 14 completed with results

Key Signals

9 with results93% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (2)
Early P 1 (1)
P 1 (1)
P 2 (2)
P 3 (8)
P 4 (3)

Trial Status

Completed14
Withdrawn4
Unknown1
Terminated1

Trial Success Rate

93.3%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT05626634Phase 2Completed

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

NCT02175173CompletedPrimary

Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome

NCT02224690Phase 3Completed

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT04133480Phase 4WithdrawnPrimary

Investigation of Cognitive Outcomes With Cannabidiol Oral Solution

NCT02815540Phase 1TerminatedPrimary

The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy

NCT01370486Phase 4WithdrawnPrimary

Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects

NCT02224573Phase 3Completed

An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes

NCT03650452Phase 2Completed

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

NCT01405053Phase 3CompletedPrimary

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

NCT01151540Phase 3CompletedPrimary

A Long Term Extension Study of E2080 in Lennox-Gastaut Patients

NCT00552045Completed

Epilepsy Phenome/Genome Project

NCT03254680Not ApplicableWithdrawn

Turmeric as Treatment in Epilepsy

NCT01160770Phase 3CompletedPrimary

Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome

NCT01146951Phase 3CompletedPrimary

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

NCT02318537Phase 3WithdrawnPrimary

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome

NCT02632149Early Phase 1UnknownPrimary

Trial to Assess Vagus Nerve Stimulation Therapy in Children With Lennox-Gastaut Syndrome

NCT02731300Phase 4CompletedPrimary

Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilot Study

NCT01991041CompletedPrimary

European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)

NCT00004729Not ApplicableCompleted

Ketogenic Diet for Child Epilepsy and Seizure Control

NCT00004776Phase 3CompletedPrimary

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome

Showing all 20 trials

Research Network

Activity Timeline